Prevention of osteoporosis: one step forward, two steps back

Area of Science:

• Endocrinology
• Geriatrics
• Pharmacology

Background:

• Hormone replacement therapy (HRT) was a primary treatment for postmenopausal osteoporosis.
• Safety concerns from a clinical trial led to decreased HRT use and its reclassification.
• Clinicians now favor alternative osteoporosis treatments, questioning HRT's safety.

Purpose of the Study:

• To evaluate the safety and efficacy of alternative osteoporosis therapies compared to HRT.
• To question the validity of HRT safety concerns.
• To advocate for HRT's return as a first-line osteoporosis treatment.

Main Methods:

• Review of existing literature on HRT and alternative osteoporosis treatments.
• Comparative analysis of safety profiles, efficacy, and costs.
• Critical assessment of safety concerns raised by previous studies.

Main Results:

• HRT demonstrates comparable safety to alternative osteoporosis treatments.
• Alternative therapies, including bisphosphonates, have their own safety considerations.
• Bisphosphonates are effective for established osteoporosis but require cautious use.

Conclusions:

• HRT is a safe and effective first-line treatment for postmenopausal osteoporosis prevention.
• Concerns about HRT safety are not fully supported when compared to alternatives.
• Cautious and selective use of bisphosphonates and emerging treatments is recommended.